Clinical and biological efficacy of tocilizumab in giant cell arteritis: Report of three patients and literature review;Efficacité clinique et biologique du tocilizumab au cours de la maladie de Horton: À propos de trois observations et revue de la littérature

Revue de Medecine Interne

Volumn 35, Issue 1, 2014, Pages 56-59

  Kieffer, P ^a   Hinschberger, O ^a   Ciobanu, E ^a   Jaeger Bizet, F ^a   Drabo, A ^a   Mostoufizadeh, T ^a   Martzolff, L ^a  

^a Hôpitaux Universitaires de Strasbourg   (France)

Author keywords

Giant cell arteritis; IL 6; Temporal arteritis; Tocilizumab; Vasculitis

Indexed keywords

CORTICOSTEROID; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; GIANT CELL ARTERITIS; HUMAN; OUTCOME ASSESSMENT; AGED; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE; FEMALE; GIANT CELL ARTERITIS; HUMANS; TREATMENT OUTCOME;

EID: 84890798641     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.12.012     Document Type: Article

References (23)

1. Singh J.A., Beg S., Lopez-Olivo M.A. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011, 38:10-20.
2. Bykerk V.P., Ostor A.J., Alvaro-Gracia J., Pavelka K., Ivorra J.A., Graninger W., et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 2012, 71:1950-1954.
3. Ogata A., Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol 2012, 2012:946048.
4. Hatz H.J., Helmke K. Polymyalgia rheumatica and giant cell arteritis: diagnosis and side effects of low-dose long-term glucocorticoid therapy. Z Rheumatol 1992, 51:213-221.
5. Pipitone N., Boiardi L., Salvarani C. Are steroids alone sufficient for the treatment of giant cell arteritis?. Best Pract Res Clin Rheumatol 2005, 19:277-292.
6. Proven A., Gabriel S.E., Orces C., O'Fallon W.M., Hunder G.G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703-708.
7. Nesher G., Sonnenblick M., Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43patients. J Rheumatol 1994, 21:1283-1286.
8. Hoffman G.S., Cid M.C., Hellmann D.B., Guillevin L., Stone J.H., Schousboe J., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002, 46:1309-1318.
9. Jover J.A., Hernandez-Garcia C., Morado I.C., Vargas E., Banares A., Fernandez-Gutierrez B. Disparate results in studies of methotrexate plus corticosteroids in the treatment of giant cell arteritis: comment on the article by Hoffman et al. Arthritis Rheum 2003, 48:1158-1159.
10. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621-630.
11. Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L., Lopez-Longo J., Figueroa M., Belzunegui J., et al. A double-blind placebo-controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630.
12. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6receptor. Rheumatology (Oxford) 2010, 49:15-24.
13. Weyand C.M., Fulbright J.W., Hunder G.G., Evans J.M., Goronzy J.J. Treatment of giant cell arteritis: interleukin-6as a biologic marker of disease activity. Arthritis Rheum 2000, 43:1041-1048.
14. Martinez-Taboada V.M., Alvarez L., RuizSoto M., Marin-Vidalled M.J., Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008, 44:207-220.
15. Thonhofer R., Hiller M., Just H., Trummer M., Siegel C., Dejaco C. Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 2011, 31:1653-1656.
16. Matsuyama M., Suzuki T., Tsuboi H., Ito S., Mamura M., Goto D., et al. Anti-interleukin-6receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007, 46:771-774.
17. Bannwarth B., Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011, 10:123-131.
18. Seitz M., Reichenbach S., Bonel H.M., Adler S., Wermelinger F., Villiger P.M. Rapid induction of remission in large vessel vasculitis by IL-6blockade. A case series. Swiss Med Wkly 2011, 141:w13156.
19. Christidis D., Jain S., Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep 2011, 2011. [PII: bcr0420114135, published online 4 July 2011]. 10.1136/bcr.04.2011.4135.
20. Beyer C., Axmann R., Sahinbegovic E., Distler J.H., Manger B., Schett G., et al. Anti-interleukin 6receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011, 70:1874-1875.
21. Sciascia S., Rossi D., Roccatello D. Interleukin 6blockade as steroid-sparing treatment for 2patients with giant cell arteritis. J Rheumatol 2011, 38:2080-2081.
22. Salvarani C., Magnani L., Catanoso M., Pipitone N., Versari A., Dardani L., et al. Tocilizumab: a novel therapy for patients with large vessel vasculitis. Rheumatology (Oxford) 2012, 51:151-156.
23. Unizony S., Arias-Urdaneta L., Miloslavsky E., Arvikar S., Khosroshahi A., Keroack B., et al. Tocilizumab for the treatment of large vessel vasculitis (giant cell arteritis, takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012, 64:1720-1729.